Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TEL-JAK2 transgenic mice develop T-cell leukemia.

C Carron1, F Cormier, A Janin

  • 1Centre National de la Recherche Scientifique (CNRS) UMR 146-Institut Curie, Centre Universitaire, Orsay, France.

Blood
|June 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutron-Multiplicity Measurement in Muon Capture on Oxygen Nuclei in the Gadolinium-Loaded Super-Kamiokande Detector.

Physical review letters·2026
Same author

Results from the T2K Experiment on Neutrino Mixing Including a New Far Detector μ-like Sample.

Physical review letters·2026
Same author

Six Years of Genetic Diagnosis of Severe Early-Onset Obesity in a French Cohort.

Obesity science & practice·2025
Same author

First Differential Measurement of the Single π^{+} Production Cross Section in Neutrino Neutral-Current Scattering.

Physical review letters·2025
Same author

First Measurement of the Electron-Neutrino Charged-Current Pion Production Cross Section on Carbon with the T2K Near Detector.

Physical review letters·2025
Same author

First Joint Oscillation Analysis of Super-Kamiokande Atmospheric and T2K Accelerator Neutrino Data.

Physical review letters·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

The TEL-JAK2 fusion gene drives leukemia in mice, causing rapid T-cell expansion and organ invasion. This study confirms TEL-JAK2 as an oncogene, highlighting its role in CD8-positive T-cell malignancies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • A chromosomal translocation t(9;12)(p24;p13) creates a TEL-JAK2 fusion gene in childhood acute T-cell leukemia.
  • The resulting TEL-JAK2 chimeric protein exhibits constitutive tyrosine kinase activity.

Purpose of the Study:

  • To investigate the in vivo properties of TEL-JAK2 in primary cells.
  • To develop a mouse model for TEL-JAK2-induced leukemia.

Main Methods:

  • Generation of transgenic mice expressing TEL-JAK2 under the EmuSRalpha enhancer/promoter.
  • Analysis of leukemic tissues for protein expression, STAT activation, and T-cell clonality (TCRbeta rearrangement).
  • In vivo transplantation of leukemic cells into nude mice.

Main Results:

Related Experiment Videos

  • Transgenic mice developed fatal leukemia with selective CD8-positive T-cell amplification.
  • Leukemic tissues showed tyrosine-phosphorylated TEL-JAK2, activated STAT1 and STAT5.
  • Leukemic T cells invaded nonhematopoietic organs (liver, brain, lung, kidney).
  • T-cell populations in leukemic organs were monoclonal/oligoclonal.

Conclusions:

  • The TEL-JAK2 fusion acts as an oncogene in vivo.
  • Expression of TEL-JAK2 in lymphoid cells leads to preferential expansion of CD8-positive T cells.
  • The TEL-JAK2 fusion is implicated in the pathogenesis of T-cell leukemia.